Cayman
Showing 40501–40650 of 45550 results
-
STING agonist 12b is an agonist of stimulator of interferon genes (STING).{59528} It binds to STING (Kd = 26.4 µM) and induces interferon reporter gene expression in cells expressing human or mouse STING (EC50s = 7.45 and 10.23 µM, respectively). STING agonist 12b (40 µM) induces expression of TNF-a, IL-6, IP-10, and IL-1b in THP-1 cells.
Brand:CaymanSKU:32521 - 1 mgAvailable on backorder
STING agonist 12b is an agonist of stimulator of interferon genes (STING).{59528} It binds to STING (Kd = 26.4 µM) and induces interferon reporter gene expression in cells expressing human or mouse STING (EC50s = 7.45 and 10.23 µM, respectively). STING agonist 12b (40 µM) induces expression of TNF-a, IL-6, IP-10, and IL-1b in THP-1 cells.
Brand:CaymanSKU:32521 - 10 mgAvailable on backorder
STING agonist 12b is an agonist of stimulator of interferon genes (STING).{59528} It binds to STING (Kd = 26.4 µM) and induces interferon reporter gene expression in cells expressing human or mouse STING (EC50s = 7.45 and 10.23 µM, respectively). STING agonist 12b (40 µM) induces expression of TNF-a, IL-6, IP-10, and IL-1b in THP-1 cells.
Brand:CaymanSKU:32521 - 5 mgAvailable on backorder
STING agonist 12b is an agonist of stimulator of interferon genes (STING).{59528} It binds to STING (Kd = 26.4 µM) and induces interferon reporter gene expression in cells expressing human or mouse STING (EC50s = 7.45 and 10.23 µM, respectively). STING agonist 12b (40 µM) induces expression of TNF-a, IL-6, IP-10, and IL-1b in THP-1 cells.
Brand:CaymanSKU:32521 - 500 µgAvailable on backorder
STING agonist 1a is an agonist of stimulator of interferon genes (STING).{57309} It induces expression of an IRF-inducible SEAP reporter gene in a cell-based assay (EC50 = 16.77 µM). STING agonist 1a (12.5-100 µM) induces expression of IFN-β, IL-6, and chemokine (C-X-C motif) ligand 10 (CXCL10) in THP-1 cells, an effect that can be reversed by STING knockout or the STING inhibitor H-151 (Item No. 25857).
Brand:CaymanSKU:32520 - 1 mgAvailable on backorder
STING agonist 1a is an agonist of stimulator of interferon genes (STING).{57309} It induces expression of an IRF-inducible SEAP reporter gene in a cell-based assay (EC50 = 16.77 µM). STING agonist 1a (12.5-100 µM) induces expression of IFN-β, IL-6, and chemokine (C-X-C motif) ligand 10 (CXCL10) in THP-1 cells, an effect that can be reversed by STING knockout or the STING inhibitor H-151 (Item No. 25857).
Brand:CaymanSKU:32520 - 10 mgAvailable on backorder
STING agonist 1a is an agonist of stimulator of interferon genes (STING).{57309} It induces expression of an IRF-inducible SEAP reporter gene in a cell-based assay (EC50 = 16.77 µM). STING agonist 1a (12.5-100 µM) induces expression of IFN-β, IL-6, and chemokine (C-X-C motif) ligand 10 (CXCL10) in THP-1 cells, an effect that can be reversed by STING knockout or the STING inhibitor H-151 (Item No. 25857).
Brand:CaymanSKU:32520 - 5 mgAvailable on backorder
STING agonist 1a is an agonist of stimulator of interferon genes (STING).{57309} It induces expression of an IRF-inducible SEAP reporter gene in a cell-based assay (EC50 = 16.77 µM). STING agonist 1a (12.5-100 µM) induces expression of IFN-β, IL-6, and chemokine (C-X-C motif) ligand 10 (CXCL10) in THP-1 cells, an effect that can be reversed by STING knockout or the STING inhibitor H-151 (Item No. 25857).
Brand:CaymanSKU:32520 - 500 µgAvailable on backorder
STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.{35844} It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o’nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR).
Brand:CaymanSKU:27886 - 1 mgAvailable on backorder
STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.{35844} It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o’nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR).
Brand:CaymanSKU:27886 - 10 mgAvailable on backorder
STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.{35844} It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o’nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR).
Brand:CaymanSKU:27886 - 5 mgAvailable on backorder
STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.{35844} It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o’nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR).
Brand:CaymanSKU:27886 - 500 µgAvailable on backorder
Stimulator of interferon genes (STING) is a component of the innate immune response that binds to cyclic dinucleotides, which are bacterial second messengers, leading to activation of NF-κB and transcription of immunomodulatory genes, including type I interferon (IFN).{22400,22401,24611,24607} The R284M mutation in STING is associated with constitutive activation of downstream signaling. It increases the propensity of STING to dimerize and associate with the kinase TBK1 (Item No. 22817), enhancing the ability of STING to activate IRF3 (Item No. 22811) and NF-κB (Item No. 10009818) and induce a type I IFN response.{41454} However, the R284M mutation occurs outside of the dimerization region between positions 153-177, so rather than a direct effect on dimerization, it is predicted to promote or inhibit binding of a cellular factor that stabilizes or impairs STING dimerization. Cayman’s STING M284 variant Monoclonal Antibody preferentially detects overexpressed STING (R284M) versus wild-type STING by Western blot and ELISA.
Brand:CaymanSKU:25922 - 100 µgAvailable on backorder
Immunogen: Synthetic peptide from the internal region of human STING protein containing the R284M mutation • Host: Mouse • Species Reactivity: (+) Human • Cross Reactivity: (-) Wild-type STING • Applications: ELISA and WB • MW = 28.8/42 kDa
Brand:CaymanSKU:25922- 100 µgAvailable on backorder
Immunogen: Synthetic peptide from the internal region of human STING protein containing the R284M mutation • Host: Mouse • Species Reactivity: (+) Human • Cross Reactivity: (-) Wild-type STING • Applications: ELISA and WB • MW = 28.8/42 kDa
Brand:CaymanSKU:25922- 100 µg
Stimulator of interferon genes (STING) is a component of the innate immune response that binds to cyclic dinucleotides, which are bacterial second messengers, leading to activation of NF-κB and transcription of immunomodulatory genes, including type I interferon (IFN).{22400,22401,24611,24607} The R284M mutation in STING is associated with constitutive activation of downstream signaling. It increases the propensity of STING to dimerize and associate with the kinase TBK1 (Item No. 22817), enhancing the ability of STING to activate IRF3 (Item No. 22811) and NF-κB (Item No. 10009818) and induce a type I IFN response.{41454} However, the R284M mutation occurs outside of the dimerization region between positions 153-177, so rather than a direct effect on dimerization, it is predicted to promote or inhibit binding of a cellular factor that stabilizes or impairs STING dimerization. Cayman’s STING M284 variant Polyclonal Antibody preferentially detects overexpressed STING (R284M) versus wild-type STING by Western blot.
Brand:CaymanSKU:24791 - 1 eaAvailable on backorder
Immunogen: Synthetic peptide from the internal region of human STING protein containing the M284 mutation • Host: Rabbit • Species reactivity: (+) Human • Cross reactivity: (-) Wild-type STING • Applications: WB
Brand:CaymanSKU:24791- 1 eaAvailable on backorder
Immunogen: Synthetic peptide from the internal region of human STING protein containing the M284 mutation • Host: Rabbit • Species reactivity: (+) Human • Cross reactivity: (-) Wild-type STING • Applications: WB
Brand:CaymanSKU:24791- 1 ea
Immunogen: Recombinant human STING protein AA 139-379 • Host: Mouse • Species Reactivity: (+) Human • Applications: ELISA, IHC, and WB • MW = 42 kDa
Brand:CaymanSKU:17856- 100 µgAvailable on backorder
Immunogen: Recombinant human STING protein AA 139-379 • Host: Mouse • Species Reactivity: (+) Human • Applications: ELISA, IHC, and WB • MW = 42 kDa
Brand:CaymanSKU:17856- 100 µg Stimulator of Interferon Genes (STING) is a component of the innate immune response. STING binds to cyclic dinucleotides, which are bacterial second messengers.{24607} Recognition of cyclic-di-GMP (c-di-GMP), c-di-AMP, or c-GMP-AMP leads to activation of NF-κB and transcription of immunomodulatory genes, including type I interferon (IFN).{22400,22401,24611} Loss of STING regulation contributes to autoimmune disorders through increased IFN activity.{24608} The gene for STING is mutated in the mouse strain Goldenticket, which consequently lacks a type I IFN response to Listeria infection.{24612} Activation of STING by the flavonoid 5,6-dimethylxanthenone-4-acetic acid (DMXAA; Item No. 14617) has been shown to kill solid tumors in mice, but the binding site of DMXAA is not conserved in human STING.{24610,24609} Cayman’s STING Monoclonal Antibody (Clone 2C8) can be used for ELISA, immunohistochemistry, and Western blot applications. The antibody recognizes STING at 42 kDa from human samples.
Brand:CaymanSKU:17856 - 100 µgAvailable on backorder
Immunogen: Human recombinant STING (Item No. 15139) • Host: Rabbit • Species Reactivity: (+) Human • Applications: ELISA, IP, and WB
Brand:CaymanSKU:17857- 1 eaAvailable on backorder
Immunogen: Human recombinant STING (Item No. 15139) • Host: Rabbit • Species Reactivity: (+) Human • Applications: ELISA, IP, and WB
Brand:CaymanSKU:17857- 1 ea Stimulator of Interferon Genes (STING) is a component of the innate immune response. STING binds to cyclic dinucleotides, which are bacterial second messengers.{24607} Recognition of cyclic-di-GMP (c-di-GMP), c-di-AMP, or c-GMP-AMP leads to activation of NF-κB and transcription of immunomodulatory genes, including type I interferon (IFN).{22400,22401,24611} Loss of STING regulation contributes to autoimmune disorders through increased IFN activity.{24608} The gene for STING is mutated in the mouse strain Goldenticket, which consequently lacks a type I IFN response to Listeria infection.{24612} Activation of STING by the flavonoid 5,6-dimethylxanthenone-4-acetic acid (DMXAA; Item No. 14617) has been shown to kill solid tumors in mice, but the binding site of DMXAA is not conserved in human STING.{24610,24609}
Brand:CaymanSKU:17857 - 1 eaAvailable on backorder
Stiripentol is a third-generation antiepileptic compound.{28852} It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits.{48495} It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.{28852,48496} Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.{28811} Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.
Brand:CaymanSKU:-Available on backorder
Stiripentol is a third-generation antiepileptic compound.{28852} It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits.{48495} It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.{28852,48496} Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.{28811} Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.
Brand:CaymanSKU:-Available on backorder
Stiripentol is a third-generation antiepileptic compound.{28852} It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits.{48495} It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.{28852,48496} Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.{28811} Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.
Brand:CaymanSKU:-Available on backorder
Stiripentol is a third-generation antiepileptic compound.{28852} It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits.{48495} It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.{28852,48496} Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.{28811} Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.
Brand:CaymanSKU:-Available on backorder
Stiripentol-d9 is intended for use as an internal standard for the quantification of stiripentol (Item No. 17781) by GC- or LC-MS. Stiripentol is a third-generation antiepileptic compound.{28852} It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing α3 subunits and to a lower extent in those containing β1 or ε subunits.{48495} It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.{28852,48496} Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.{28811} Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.
Brand:CaymanSKU:28506 - 1 mgAvailable on backorder
STK16-IN-1 is an inhibitor of the serine/threonine kinase STK16 (IC50 = 295 nM).{46178} It is selective for STK16 over mTOR, PI3Kδ, and PI3Kγ in an enzyme assay (IC50s = 5,560, 856, and 867 nM, respectively) and over 440 additional kinases in a KinomeScan profiling assay. It decreases the growth of MCF-7 cells (GI50 = ~10 µM) and increases the number of binucleated cells. STK16-IN-1 (2.5-5 µM) potentiates the antiproliferative effects of colchicine (Item No. 9000760), paclitaxel (Item No. 10461), doxorubicin (Item No. 15007), and cisplatin (Item No. 13119) in MCF-7 cells.
Brand:CaymanSKU:27370 - 10 mgAvailable on backorder
STK16-IN-1 is an inhibitor of the serine/threonine kinase STK16 (IC50 = 295 nM).{46178} It is selective for STK16 over mTOR, PI3Kδ, and PI3Kγ in an enzyme assay (IC50s = 5,560, 856, and 867 nM, respectively) and over 440 additional kinases in a KinomeScan profiling assay. It decreases the growth of MCF-7 cells (GI50 = ~10 µM) and increases the number of binucleated cells. STK16-IN-1 (2.5-5 µM) potentiates the antiproliferative effects of colchicine (Item No. 9000760), paclitaxel (Item No. 10461), doxorubicin (Item No. 15007), and cisplatin (Item No. 13119) in MCF-7 cells.
Brand:CaymanSKU:27370 - 25 mgAvailable on backorder
STK16-IN-1 is an inhibitor of the serine/threonine kinase STK16 (IC50 = 295 nM).{46178} It is selective for STK16 over mTOR, PI3Kδ, and PI3Kγ in an enzyme assay (IC50s = 5,560, 856, and 867 nM, respectively) and over 440 additional kinases in a KinomeScan profiling assay. It decreases the growth of MCF-7 cells (GI50 = ~10 µM) and increases the number of binucleated cells. STK16-IN-1 (2.5-5 µM) potentiates the antiproliferative effects of colchicine (Item No. 9000760), paclitaxel (Item No. 10461), doxorubicin (Item No. 15007), and cisplatin (Item No. 13119) in MCF-7 cells.
Brand:CaymanSKU:27370 - 5 mgAvailable on backorder
STK16-IN-1 is an inhibitor of the serine/threonine kinase STK16 (IC50 = 295 nM).{46178} It is selective for STK16 over mTOR, PI3Kδ, and PI3Kγ in an enzyme assay (IC50s = 5,560, 856, and 867 nM, respectively) and over 440 additional kinases in a KinomeScan profiling assay. It decreases the growth of MCF-7 cells (GI50 = ~10 µM) and increases the number of binucleated cells. STK16-IN-1 (2.5-5 µM) potentiates the antiproliferative effects of colchicine (Item No. 9000760), paclitaxel (Item No. 10461), doxorubicin (Item No. 15007), and cisplatin (Item No. 13119) in MCF-7 cells.
Brand:CaymanSKU:27370 - 50 mgAvailable on backorder
15-hydroxy prostaglandin dehydrogenase (15-hydroxy PGDH) is a key enzyme involved in the inactivation of PGs and related eiscosanoids.{20452} It functions by catalyzing the oxidation of primary PGs to their 15-keto metabolites. Two types of 15-hydroxy PGDH have been identified: type-I is NAD+-dependent primarily using eicosanoids as substrates, while type-II uses either NAD+ or NADP+ as cofactors and bears broader substrate specificity.{20452} STK393606 is a competitive inhibitor of NAD+-dependent type-I 15-hydroxy PGDH with an IC50 value of 26.4 nM and a Ki value of 5 nM.{21861} It demonstrates selectivity for 15-hydroxy PGDH when profiled across a panel of related dehydrogenase or reductase enzymes.{21861}
Brand:CaymanSKU:- 15-hydroxy prostaglandin dehydrogenase (15-hydroxy PGDH) is a key enzyme involved in the inactivation of PGs and related eiscosanoids.{20452} It functions by catalyzing the oxidation of primary PGs to their 15-keto metabolites. Two types of 15-hydroxy PGDH have been identified: type-I is NAD+-dependent primarily using eicosanoids as substrates, while type-II uses either NAD+ or NADP+ as cofactors and bears broader substrate specificity.{20452} STK393606 is a competitive inhibitor of NAD+-dependent type-I 15-hydroxy PGDH with an IC50 value of 26.4 nM and a Ki value of 5 nM.{21861} It demonstrates selectivity for 15-hydroxy PGDH when profiled across a panel of related dehydrogenase or reductase enzymes.{21861}
Brand:CaymanSKU:- 15-hydroxy prostaglandin dehydrogenase (15-hydroxy PGDH) is a key enzyme involved in the inactivation of PGs and related eiscosanoids.{20452} It functions by catalyzing the oxidation of primary PGs to their 15-keto metabolites. Two types of 15-hydroxy PGDH have been identified: type-I is NAD+-dependent primarily using eicosanoids as substrates, while type-II uses either NAD+ or NADP+ as cofactors and bears broader substrate specificity.{20452} STK393606 is a competitive inhibitor of NAD+-dependent type-I 15-hydroxy PGDH with an IC50 value of 26.4 nM and a Ki value of 5 nM.{21861} It demonstrates selectivity for 15-hydroxy PGDH when profiled across a panel of related dehydrogenase or reductase enzymes.{21861}
Brand:CaymanSKU:- 15-hydroxy prostaglandin dehydrogenase (15-hydroxy PGDH) is a key enzyme involved in the inactivation of PGs and related eiscosanoids.{20452} It functions by catalyzing the oxidation of primary PGs to their 15-keto metabolites. Two types of 15-hydroxy PGDH have been identified: type-I is NAD+-dependent primarily using eicosanoids as substrates, while type-II uses either NAD+ or NADP+ as cofactors and bears broader substrate specificity.{20452} STK393606 is a competitive inhibitor of NAD+-dependent type-I 15-hydroxy PGDH with an IC50 value of 26.4 nM and a Ki value of 5 nM.{21861} It demonstrates selectivity for 15-hydroxy PGDH when profiled across a panel of related dehydrogenase or reductase enzymes.{21861}
Brand:CaymanSKU:-
STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour .{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:31358 - 1 mgAvailable on backorder
STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour .{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:31358 - 10 mgAvailable on backorder
STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour .{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:31358 - 25 mgAvailable on backorder
STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour .{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:31358 - 5 mgAvailable on backorder
STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour.{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:- STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour.{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:- STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour.{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:- STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour.{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}
Brand:CaymanSKU:-
Streptavidin conjugated to SureLight® APC – Optimized for protein interaction assays Binding Moiety: Streptavidin Dye: SureLight® Allophycocyanin (APC) Excitation max. λ: 652 nm Emission max. λ: 657.5 nm F:P: 1:1.5 Uses: Optimized for High throughput screening (HTS) and fluorescence resonance energy transfer (FRET) assays targeting protein interactions, flow cytometry
Brand:CaymanSKU:16631 - 1 mgAvailable on backorder
Streptazolin is a fungal metabolite originally isolated from S. viridochromogenes.{49059} It increases NF-κB activity when used at concentrations ranging from 60 to 130 µg/ml, at least in part, via PI3K signaling.{49060} Streptazolin enhances TNF-α secretion induced by LPS and enhances IL-8 secretion when used alone or in combination with LPS in THP-1 Blue cells.
Brand:CaymanSKU:27266 - 1 mgAvailable on backorder
Streptazolin is a fungal metabolite originally isolated from S. viridochromogenes.{49059} It increases NF-κB activity when used at concentrations ranging from 60 to 130 µg/ml, at least in part, via PI3K signaling.{49060} Streptazolin enhances TNF-α secretion induced by LPS and enhances IL-8 secretion when used alone or in combination with LPS in THP-1 Blue cells.
Brand:CaymanSKU:27266 - 5 mgAvailable on backorder
Streptimidone is a bacterial metabolite that has been found in Streptomyces and has diverse biological activities.{52313,52314,52315} It inhibits protein synthesis in a cell-free assay when used at a concentration of 50 μg/ml.{52314} Streptimidone (20 and 100 μg/disc) inhibits the growth of S. cerevisiae and the plant pathogenic fungus C. miyabeanus in a disc diffusion assay.{52313} It reduces tumor growth in H.S. No. 1 human sarcoma and H.Ep. No. 3 human epidermoid carcinoma rat xenograft models when administered at doses of 12.5 and 25 mg/kg per day.{52315}
Brand:CaymanSKU:29984 - 5 mgAvailable on backorder
Streptimidone is a bacterial metabolite that has been found in Streptomyces and has diverse biological activities.{52313,52314,52315} It inhibits protein synthesis in a cell-free assay when used at a concentration of 50 μg/ml.{52314} Streptimidone (20 and 100 μg/disc) inhibits the growth of S. cerevisiae and the plant pathogenic fungus C. miyabeanus in a disc diffusion assay.{52313} It reduces tumor growth in H.S. No. 1 human sarcoma and H.Ep. No. 3 human epidermoid carcinoma rat xenograft models when administered at doses of 12.5 and 25 mg/kg per day.{52315}
Brand:CaymanSKU:29984 - 500 µgAvailable on backorder
Streptochlorin is a bacterial metabolite originally isolated from Streptomyces sp. SF2583 that has diverse biological activities, including antiangiogenic, antiproliferative, and anti-allergic properties.{46236,46237,46238,46239} It inhibits TNF-α-induced NF-κB transcriptional activity and decreases proliferation of human umbilical vein endothelial cells (HUVECs) when used at concentrations ranging from 5 to 20 µM.{46237} Streptochlorin (12 µg/ml) decreases viability of, as well as induces apoptosis and increases the production of reactive oxygen species (ROS) in, Hep3B human hepatocellular carcinoma cells.{46238} It does not induce cytotoxicity in RBL-2H3 mast cells at concentrations up to 100 µM.{46239} Streptochlorin prevents degranulation in antigen-stimulated mast cells, as well as inhibits Syk kinase and the Src family kinases LYN and Fyn and reduces the secretion of TNF-α and IL-4 induced by dinitrophenyl-human serum album (DNP-HSA) in RBL-2H3 mast cells. It also decreases swelling and reduces scratching behavior in a mouse model of allergic dermatitis induced by dinitrofluorobenzene (DNFB).
Brand:CaymanSKU:27605 - 1 mgAvailable on backorder
Streptochlorin is a bacterial metabolite originally isolated from Streptomyces sp. SF2583 that has diverse biological activities, including antiangiogenic, antiproliferative, and anti-allergic properties.{46236,46237,46238,46239} It inhibits TNF-α-induced NF-κB transcriptional activity and decreases proliferation of human umbilical vein endothelial cells (HUVECs) when used at concentrations ranging from 5 to 20 µM.{46237} Streptochlorin (12 µg/ml) decreases viability of, as well as induces apoptosis and increases the production of reactive oxygen species (ROS) in, Hep3B human hepatocellular carcinoma cells.{46238} It does not induce cytotoxicity in RBL-2H3 mast cells at concentrations up to 100 µM.{46239} Streptochlorin prevents degranulation in antigen-stimulated mast cells, as well as inhibits Syk kinase and the Src family kinases LYN and Fyn and reduces the secretion of TNF-α and IL-4 induced by dinitrophenyl-human serum album (DNP-HSA) in RBL-2H3 mast cells. It also decreases swelling and reduces scratching behavior in a mouse model of allergic dermatitis induced by dinitrofluorobenzene (DNFB).
Brand:CaymanSKU:27605 - 5 mgAvailable on backorder
Streptomycin is an aminoglycoside antibiotic that inhibits growth of both Gram-negative (MICs = 1 and 16 μg/mL for K. pneumoniae and S. marcescens, respectively) and Gram-positive bacteria (MIC = 0.25 μg/mL for S. pneumoniae).{40530} It inhibits growth of M. tuberculosis H37Rv (MIC = 5 μg/mL) and of susceptible strains from clinical isolates (MICs = ≤0.125-1 μg/mL).{40531,40532} Streptomycin (150 mg/kg), in combination with isoniazid (Item No. 20378), rifapentine (Item No. 20307), and moxifloxacin (Item No. 14830), administered once per week over 6 months to M. tuberculosis-inoculated mice results in clearance of the pathogen from the lungs of the majority of treated mice.{37311} However, after 3 months without treatment, 58% of treated mice produce a positive lung culture. Streptomycin acts by inhibiting protein synthesis in prokaryotes by binding to the 30S ribosomal subunit.{40528,37308,37310,40529} It has been used, in combination with penicillin G (Item No. 21615), in antibiotic cocktails to prevent bacterial growth in cell culture.{37309} Formulations containing streptomycin in combination with other antibiotics have been used to treat tuberculosis.
Brand:CaymanSKU:21211 -Out of stock
Streptomycin is an aminoglycoside antibiotic that inhibits growth of both Gram-negative (MICs = 1 and 16 μg/mL for K. pneumoniae and S. marcescens, respectively) and Gram-positive bacteria (MIC = 0.25 μg/mL for S. pneumoniae).{40530} It inhibits growth of M. tuberculosis H37Rv (MIC = 5 μg/mL) and of susceptible strains from clinical isolates (MICs = ≤0.125-1 μg/mL).{40531,40532} Streptomycin (150 mg/kg), in combination with isoniazid (Item No. 20378), rifapentine (Item No. 20307), and moxifloxacin (Item No. 14830), administered once per week over 6 months to M. tuberculosis-inoculated mice results in clearance of the pathogen from the lungs of the majority of treated mice.{37311} However, after 3 months without treatment, 58% of treated mice produce a positive lung culture. Streptomycin acts by inhibiting protein synthesis in prokaryotes by binding to the 30S ribosomal subunit.{40528,37308,37310,40529} It has been used, in combination with penicillin G (Item No. 21615), in antibiotic cocktails to prevent bacterial growth in cell culture.{37309} Formulations containing streptomycin in combination with other antibiotics have been used to treat tuberculosis.
Brand:CaymanSKU:21211 -Out of stock
Streptomycin is an aminoglycoside antibiotic that inhibits growth of both Gram-negative (MICs = 1 and 16 μg/mL for K. pneumoniae and S. marcescens, respectively) and Gram-positive bacteria (MIC = 0.25 μg/mL for S. pneumoniae).{40530} It inhibits growth of M. tuberculosis H37Rv (MIC = 5 μg/mL) and of susceptible strains from clinical isolates (MICs = ≤0.125-1 μg/mL).{40531,40532} Streptomycin (150 mg/kg), in combination with isoniazid (Item No. 20378), rifapentine (Item No. 20307), and moxifloxacin (Item No. 14830), administered once per week over 6 months to M. tuberculosis-inoculated mice results in clearance of the pathogen from the lungs of the majority of treated mice.{37311} However, after 3 months without treatment, 58% of treated mice produce a positive lung culture. Streptomycin acts by inhibiting protein synthesis in prokaryotes by binding to the 30S ribosomal subunit.{40528,37308,37310,40529} It has been used, in combination with penicillin G (Item No. 21615), in antibiotic cocktails to prevent bacterial growth in cell culture.{37309} Formulations containing streptomycin in combination with other antibiotics have been used to treat tuberculosis.
Brand:CaymanSKU:21211 -Out of stock
Streptomycin is an aminoglycoside antibiotic that inhibits growth of both Gram-negative (MICs = 1 and 16 μg/mL for K. pneumoniae and S. marcescens, respectively) and Gram-positive bacteria (MIC = 0.25 μg/mL for S. pneumoniae).{40530} It inhibits growth of M. tuberculosis H37Rv (MIC = 5 μg/mL) and of susceptible strains from clinical isolates (MICs = ≤0.125-1 μg/mL).{40531,40532} Streptomycin (150 mg/kg), in combination with isoniazid (Item No. 20378), rifapentine (Item No. 20307), and moxifloxacin (Item No. 14830), administered once per week over 6 months to M. tuberculosis-inoculated mice results in clearance of the pathogen from the lungs of the majority of treated mice.{37311} However, after 3 months without treatment, 58% of treated mice produce a positive lung culture. Streptomycin acts by inhibiting protein synthesis in prokaryotes by binding to the 30S ribosomal subunit.{40528,37308,37310,40529} It has been used, in combination with penicillin G (Item No. 21615), in antibiotic cocktails to prevent bacterial growth in cell culture.{37309} Formulations containing streptomycin in combination with other antibiotics have been used to treat tuberculosis.
Brand:CaymanSKU:21211 -Out of stock
Streptonigrin is a phenylpyridylquinoline originally isolated from S. flocculus with diverse biological activities.{46268,46267,46269,46265,46266,46270} Streptonigrin (2.5-12.5 μM) induces DNA cleavage by calf thymus topoisomerase II in a concentration-dependent manner.{46268} It induces phage production in S. typhimurium when used at concentrations ranging from 1 to 10 μg/ml.{46267} Streptonigrin (10 μg/ml) inhibits DNA synthesis in and reduces survival of S. typhimurium bacteria. Streptonigrin is bactericidal against E. coli in an iron-dependent manner, an effect that is blocked by the iron chelators deferoxamine (Item No. 14595) and orthophenanthroline.{46269} Streptonigrin (40 nM) is cytotoxic to human HT-29 colon carcinoma cells but not to BE colon carcinoma cells in which NAD(P)H:quinone oxidoreductase is not expressed.{46265} Streptonigrin (0.001-0.1 μg/ml) inhibits mitosis and induces chromatin breaks in human leukocytes in a concentration-dependent manner.{46266} In vivo, streptonigrin (0.05 mg/kg, i.p.) increases the mean survival time in rats infected with Rauscher virus.{46270}
Brand:CaymanSKU:27952 - 1 mgAvailable on backorder
Streptonigrin is a phenylpyridylquinoline originally isolated from S. flocculus with diverse biological activities.{46268,46267,46269,46265,46266,46270} Streptonigrin (2.5-12.5 μM) induces DNA cleavage by calf thymus topoisomerase II in a concentration-dependent manner.{46268} It induces phage production in S. typhimurium when used at concentrations ranging from 1 to 10 μg/ml.{46267} Streptonigrin (10 μg/ml) inhibits DNA synthesis in and reduces survival of S. typhimurium bacteria. Streptonigrin is bactericidal against E. coli in an iron-dependent manner, an effect that is blocked by the iron chelators deferoxamine (Item No. 14595) and orthophenanthroline.{46269} Streptonigrin (40 nM) is cytotoxic to human HT-29 colon carcinoma cells but not to BE colon carcinoma cells in which NAD(P)H:quinone oxidoreductase is not expressed.{46265} Streptonigrin (0.001-0.1 μg/ml) inhibits mitosis and induces chromatin breaks in human leukocytes in a concentration-dependent manner.{46266} In vivo, streptonigrin (0.05 mg/kg, i.p.) increases the mean survival time in rats infected with Rauscher virus.{46270}
Brand:CaymanSKU:27952 - 5 mgAvailable on backorder
Streptozotocin (STZ) is a glucosamine-nitrosourea which is commonly used to induce experimental diabetes in animals.{21671,21669} It specifically targets beta cells, entering via the glucose transporter GLUT2 and causing alkylation of DNA.{21670,21667} DNA damage induces activation of poly ADP-ribosylation, depletion of cellular NAD+ and ATP, and formation of superoxide radicals, leading to the destruction of beta cells.{21671} The effectiveness of STZ depends on the level of GLUT2 expression, which in turn may be influenced by age, sex, strain, or species.{21669,21668}
Brand:CaymanSKU:- Streptozotocin (STZ) is a glucosamine-nitrosourea which is commonly used to induce experimental diabetes in animals.{21671,21669} It specifically targets beta cells, entering via the glucose transporter GLUT2 and causing alkylation of DNA.{21670,21667} DNA damage induces activation of poly ADP-ribosylation, depletion of cellular NAD+ and ATP, and formation of superoxide radicals, leading to the destruction of beta cells.{21671} The effectiveness of STZ depends on the level of GLUT2 expression, which in turn may be influenced by age, sex, strain, or species.{21669,21668}
Brand:CaymanSKU:- Streptozotocin (STZ) is a glucosamine-nitrosourea which is commonly used to induce experimental diabetes in animals.{21671,21669} It specifically targets beta cells, entering via the glucose transporter GLUT2 and causing alkylation of DNA.{21670,21667} DNA damage induces activation of poly ADP-ribosylation, depletion of cellular NAD+ and ATP, and formation of superoxide radicals, leading to the destruction of beta cells.{21671} The effectiveness of STZ depends on the level of GLUT2 expression, which in turn may be influenced by age, sex, strain, or species.{21669,21668}
Brand:CaymanSKU:- Streptozotocin (STZ) is a glucosamine-nitrosourea which is commonly used to induce experimental diabetes in animals.{21671,21669} It specifically targets beta cells, entering via the glucose transporter GLUT2 and causing alkylation of DNA.{21670,21667} DNA damage induces activation of poly ADP-ribosylation, depletion of cellular NAD+ and ATP, and formation of superoxide radicals, leading to the destruction of beta cells.{21671} The effectiveness of STZ depends on the level of GLUT2 expression, which in turn may be influenced by age, sex, strain, or species.{21669,21668}
Brand:CaymanSKU:-
Strontium ranelate is an antiosteoporotic agent.{52484} It inhibits 1,25-dihydroxyvitamin D3-induced increases in the levels of carbonic anhydrase II and the vitronectin receptor, markers of osteoclast differentiation, in isolated chicken bone marrow cells when used at concentrations of 0.1, 0.5, and 1 mM. Pretreatment or continuous treatment of bovine bone slices with strontium ranelate (1 mM) inhibits bone resorption by isolated rat osteoclasts. Strontium ranelate (750 mg/kg per day) decreases osteoclast surface and number, indicating inhibition of bone resorption, but has no effect on the bone formation rate or mineral apposition rate, indicating maintenance of bone formation, in the alveolar bone in adult cynomolgus monkeys.{52485}
Brand:CaymanSKU:30272 - 10 mgAvailable on backorder
Strontium ranelate is an antiosteoporotic agent.{52484} It inhibits 1,25-dihydroxyvitamin D3-induced increases in the levels of carbonic anhydrase II and the vitronectin receptor, markers of osteoclast differentiation, in isolated chicken bone marrow cells when used at concentrations of 0.1, 0.5, and 1 mM. Pretreatment or continuous treatment of bovine bone slices with strontium ranelate (1 mM) inhibits bone resorption by isolated rat osteoclasts. Strontium ranelate (750 mg/kg per day) decreases osteoclast surface and number, indicating inhibition of bone resorption, but has no effect on the bone formation rate or mineral apposition rate, indicating maintenance of bone formation, in the alveolar bone in adult cynomolgus monkeys.{52485}
Brand:CaymanSKU:30272 - 100 mgAvailable on backorder
Strontium ranelate is an antiosteoporotic agent.{52484} It inhibits 1,25-dihydroxyvitamin D3-induced increases in the levels of carbonic anhydrase II and the vitronectin receptor, markers of osteoclast differentiation, in isolated chicken bone marrow cells when used at concentrations of 0.1, 0.5, and 1 mM. Pretreatment or continuous treatment of bovine bone slices with strontium ranelate (1 mM) inhibits bone resorption by isolated rat osteoclasts. Strontium ranelate (750 mg/kg per day) decreases osteoclast surface and number, indicating inhibition of bone resorption, but has no effect on the bone formation rate or mineral apposition rate, indicating maintenance of bone formation, in the alveolar bone in adult cynomolgus monkeys.{52485}
Brand:CaymanSKU:30272 - 250 mgAvailable on backorder
Strontium ranelate is an antiosteoporotic agent.{52484} It inhibits 1,25-dihydroxyvitamin D3-induced increases in the levels of carbonic anhydrase II and the vitronectin receptor, markers of osteoclast differentiation, in isolated chicken bone marrow cells when used at concentrations of 0.1, 0.5, and 1 mM. Pretreatment or continuous treatment of bovine bone slices with strontium ranelate (1 mM) inhibits bone resorption by isolated rat osteoclasts. Strontium ranelate (750 mg/kg per day) decreases osteoclast surface and number, indicating inhibition of bone resorption, but has no effect on the bone formation rate or mineral apposition rate, indicating maintenance of bone formation, in the alveolar bone in adult cynomolgus monkeys.{52485}
Brand:CaymanSKU:30272 - 50 mgAvailable on backorder
Brand:CaymanSKU:29988 - 1 mgAvailable on backorder
Brand:CaymanSKU:29988 - 5 mgAvailable on backorder
STX140 is an estrogen sulfamate with anticancer activities.{48571} It inhibits steroid sulfatase with IC50 values of 39 and 0.5 nM in placental microsomes and MCF-7 cancer cells, respectively. STX140 also binds to carbonic anhydrase IX and II (Kis = 70 and 270 nM, respectively).{35834} It inhibits bovine brain tubulin assembly in a cell-free assay (IC50 = 2.2 µM) and tubule formation in human umbilical vein epithelial cells (HUVECs) when used at concentrations of 50 and 100 nM.{48572,48573} STX140 inhibits proliferation of LNCaP, PC3, and MDA-MB-231 cancer cells, as well as wild-type A2780 cancer cells and adriamycin- and cisplatin-resistant A2780 cancer cells (IC50s = 530, 400, 618, 330, 870, and 380 nM, respectively).{48574,48575} It reduces angiogenesis in a Matrigel™ plug assay in mice and tumor growth in MCF-7 and MDA-MB-231 mouse xenograft models when used at a dose of 20 mg/kg.{48576,48575}
Brand:CaymanSKU:27863 - 1 mgAvailable on backorder
STX140 is an estrogen sulfamate with anticancer activities.{48571} It inhibits steroid sulfatase with IC50 values of 39 and 0.5 nM in placental microsomes and MCF-7 cancer cells, respectively. STX140 also binds to carbonic anhydrase IX and II (Kis = 70 and 270 nM, respectively).{35834} It inhibits bovine brain tubulin assembly in a cell-free assay (IC50 = 2.2 µM) and tubule formation in human umbilical vein epithelial cells (HUVECs) when used at concentrations of 50 and 100 nM.{48572,48573} STX140 inhibits proliferation of LNCaP, PC3, and MDA-MB-231 cancer cells, as well as wild-type A2780 cancer cells and adriamycin- and cisplatin-resistant A2780 cancer cells (IC50s = 530, 400, 618, 330, 870, and 380 nM, respectively).{48574,48575} It reduces angiogenesis in a Matrigel™ plug assay in mice and tumor growth in MCF-7 and MDA-MB-231 mouse xenograft models when used at a dose of 20 mg/kg.{48576,48575}
Brand:CaymanSKU:27863 - 10 mgAvailable on backorder
STX140 is an estrogen sulfamate with anticancer activities.{48571} It inhibits steroid sulfatase with IC50 values of 39 and 0.5 nM in placental microsomes and MCF-7 cancer cells, respectively. STX140 also binds to carbonic anhydrase IX and II (Kis = 70 and 270 nM, respectively).{35834} It inhibits bovine brain tubulin assembly in a cell-free assay (IC50 = 2.2 µM) and tubule formation in human umbilical vein epithelial cells (HUVECs) when used at concentrations of 50 and 100 nM.{48572,48573} STX140 inhibits proliferation of LNCaP, PC3, and MDA-MB-231 cancer cells, as well as wild-type A2780 cancer cells and adriamycin- and cisplatin-resistant A2780 cancer cells (IC50s = 530, 400, 618, 330, 870, and 380 nM, respectively).{48574,48575} It reduces angiogenesis in a Matrigel™ plug assay in mice and tumor growth in MCF-7 and MDA-MB-231 mouse xenograft models when used at a dose of 20 mg/kg.{48576,48575}
Brand:CaymanSKU:27863 - 5 mgAvailable on backorder
STY-BODIPY is a styrene-conjugated fluorogenic probe for radical-trapping antioxidant (RTA) activity.{35900} Co-autoxidation of the STY-BODIPY signal carrier and a hydrocarbon co-substrate can be quantified by monitoring the loss of absorbance at 571 nm. STY-BODIPY has been used to measure the activity of RTAs, as well as the kinetics and stoichiometry of RTA reactions in cell-free assays.{35900,43390,45367}
Brand:CaymanSKU:27089 - 1 mgAvailable on backorder
STY-BODIPY is a styrene-conjugated fluorogenic probe for radical-trapping antioxidant (RTA) activity.{35900} Co-autoxidation of the STY-BODIPY signal carrier and a hydrocarbon co-substrate can be quantified by monitoring the loss of absorbance at 571 nm. STY-BODIPY has been used to measure the activity of RTAs, as well as the kinetics and stoichiometry of RTA reactions in cell-free assays.{35900,43390,45367}
Brand:CaymanSKU:27089 - 5 mgAvailable on backorder
STY-BODIPY is a styrene-conjugated fluorogenic probe for radical-trapping antioxidant (RTA) activity.{35900} Co-autoxidation of the STY-BODIPY signal carrier and a hydrocarbon co-substrate can be quantified by monitoring the loss of absorbance at 571 nm. STY-BODIPY has been used to measure the activity of RTAs, as well as the kinetics and stoichiometry of RTA reactions in cell-free assays.{35900,43390,45367}
Brand:CaymanSKU:27089 - 500 µgAvailable on backorder
SU 14813 is a dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively).{58125} It is selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively). SU 14813 inhibits VEGFR2, PDGFRβ, KIT, and FLT3-internal tandem duplication (FLT3-ITD) phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively). It inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation. SU 14813 inhibits VEGF-induced survival of human umbilical vein endothelial cells (HUVECs; IC50 = 6.8 nM). It reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10 to 80 mg/kg twice per day.
Brand:CaymanSKU:31514 - 100 mgAvailable on backorder
SU 14813 is a dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively).{58125} It is selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively). SU 14813 inhibits VEGFR2, PDGFRβ, KIT, and FLT3-internal tandem duplication (FLT3-ITD) phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively). It inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation. SU 14813 inhibits VEGF-induced survival of human umbilical vein endothelial cells (HUVECs; IC50 = 6.8 nM). It reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10 to 80 mg/kg twice per day.
Brand:CaymanSKU:31514 - 25 mgAvailable on backorder
SU 14813 is a dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively).{58125} It is selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively). SU 14813 inhibits VEGFR2, PDGFRβ, KIT, and FLT3-internal tandem duplication (FLT3-ITD) phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively). It inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation. SU 14813 inhibits VEGF-induced survival of human umbilical vein endothelial cells (HUVECs; IC50 = 6.8 nM). It reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10 to 80 mg/kg twice per day.
Brand:CaymanSKU:31514 - 5 mgAvailable on backorder
SU 14813 is a dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively).{58125} It is selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively). SU 14813 inhibits VEGFR2, PDGFRβ, KIT, and FLT3-internal tandem duplication (FLT3-ITD) phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively). It inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation. SU 14813 inhibits VEGF-induced survival of human umbilical vein endothelial cells (HUVECs; IC50 = 6.8 nM). It reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10 to 80 mg/kg twice per day.
Brand:CaymanSKU:31514 - 50 mgAvailable on backorder
SU 1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM), having negligible activity at several other serine/threonine and tyrosine kinases.{26805,23658} It effectively blocks signaling through VEGFR2 both in vitro and in vivo.{26805,26806} SU 1498 is used to study the role of VEGFR2 signaling in diverse processes, including angiogenesis, tumor growth, neural progenitor cell survival, and neuroregeneration.{26806,26802,26803,26804}
Brand:CaymanSKU:-Out of stock
SU 1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM), having negligible activity at several other serine/threonine and tyrosine kinases.{26805,23658} It effectively blocks signaling through VEGFR2 both in vitro and in vivo.{26805,26806} SU 1498 is used to study the role of VEGFR2 signaling in diverse processes, including angiogenesis, tumor growth, neural progenitor cell survival, and neuroregeneration.{26806,26802,26803,26804}
Brand:CaymanSKU:-Out of stock
SU 1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM), having negligible activity at several other serine/threonine and tyrosine kinases.{26805,23658} It effectively blocks signaling through VEGFR2 both in vitro and in vivo.{26805,26806} SU 1498 is used to study the role of VEGFR2 signaling in diverse processes, including angiogenesis, tumor growth, neural progenitor cell survival, and neuroregeneration.{26806,26802,26803,26804}
Brand:CaymanSKU:-Out of stock